miR-181b在弥漫大B细胞淋巴瘤中表达及功能研究  

Expression and Function of miR-181b in Diffuse Large B Cell Lymphoma

作　　者：贺白[1] 朱丹霞[2] 晁红颖[3] HE Bai;ZHU Dan-Xia;CHAO Hong-Ying(Department of Hematology;Department of Oncology,Changzhou First People＇s Hospital,Changzhou 213000,Jiangsu Province,Chi-na;Department of Hematology,Changzhou Second People＇s Hospital,Changzhou 213000,Jiangsu Province,China)

机构地区：[1]常州市第一人民医院血液科,江苏常州213000 [2]常州市第一人民医院肿瘤科,江苏常州213000 [3]常州市第二人民医院血液科,江苏常州213000

出　　处：《中国实验血液学杂志》2018年第4期1111-1115,共5页Journal of Experimental Hematology

基　　金：国自然青年科学基金(81302047)

摘　　要：目的:探讨miR-181b在弥漫大B细胞淋巴瘤(DLBCL)中表达及其功能。方法:选择2010年3月到2012年3月来我院及常州市第二人民医院进行检查和治疗的124例DLBCL患者的淋巴组织样本,作为DLBCL组;另选择64例经检查确定为非淋巴瘤患者的健康淋巴组织,作为对照组。检测两组淋巴样本中miR-181b的表达水平,比较不同临床特征的淋巴瘤患者淋巴组织中miR-181b的表达水平,比较不同组织miR-181b表达水平的淋巴瘤患者的生存情况。结果:DLBCL患者淋巴组织中miR-181b的相对表达量显著高于健康淋巴组织(P<0.05)。Ann Arbor分期越高的患者淋巴组织中miR-181b的相对表达量越高(P<0.05),而IPI评分越高的患者淋巴组织中miR-181b的相对表达量也越高(P<0.05)。miR-181b低表达组患者5年生存率显著高于高表达组患者(P<0.05)。结论:miR-181b在不同临床分期和预后的DLBCL患者淋巴组织中表达存在差异,它有可能成为未来对DLBCL诊断和预后监测的有效指标。Objective： To investigate the expression and function of miR-181 b in diffuse large B cell lymphoma（ DLBCL）. Methods： The lymphoid tissues of 124 patients with DLBCL examined and treated in our hospital from March 2010 to March 2012 were used as the DLBCL group. The healthy lympaid dissases in another 64 patients with non lymphaoma were selected as the control group. The expression levels of miR-181 b in two groups were detected,and the expression levels of miR-181 b in lymphoid tissues of DLBCL patients with different clinical features were compared. The survival of DLBCL patients with different levels of miR-181 b expression was compared. Results： The relative expression level of miR-181 b in lymph tissues of DLBCL patients was significantly higher than that in healthy lymphoid tissues（ P〈0. 05）. The higher the Ann Arbor staging was,the higher the relative expression of miR-181 b was in lymphoid tissues（ P〈0. 05）,and the higher the IPI score was,the higher the relative expression of miR-181 b was in lymphoid tissues（ P〈0. 05）. The 5-year survival rate of the patients with miR-181 b low expression was significantly higher than that of patients with miR-181 b high expression（ P〈0. 05）. Conclusion： There are differences in the expression of miR-181 b in lymphoid tissues of DLBCL patients with different clinical stages and prognosis. It may become an effective indicator for the diagnosis and prognosis evaluation of DLBCL.

关 键 词：弥漫性大B淋巴细胞瘤 miR-181b 基因表达 

分 类 号：R733.1[医药卫生—肿瘤]